Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
Distinctive Features of Adult Stem Cells vs Cancer Stem Cells01:18

Distinctive Features of Adult Stem Cells vs Cancer Stem Cells

A stem cell is an unspecialized cell that can divide without limit as needed and can, under specific conditions, differentiate into specialized cells.
Adult stem cells
Adult stem cells are tissue-specific; hence, they divide to develop the tissue from which they originate. One type of adult stem cell is the epithelial stem cell, which gives rise to the keratinocytes in the multiple layers of epithelial cells in the epidermis of the skin. Adult bone marrow has three distinct types of stem cells:...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Photobiomodulation in the infrared spectrum reverses the expansion of circulating natural killer cells and brain microglial activation in Sanfilippo mice.

Journal of neurochemistry·2024
Same author

High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Bone marrow transplantation·2017
Same author

Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy.

Cancer chemotherapy and pharmacology·2017
Same author

Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor.

Bone marrow transplantation·2014
Same author

Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment.

Bone marrow transplantation·2013
Same author

MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

Leukemia·2012
Same journal

Analysis of Second Primary Tumours in Cutaneous Lymphoma Populations.

Cancer investigation·2026
Same journal

The Heterogeneity of B Cells Potentially Contributes to Metastasis of Clear Cell Renal Cell Carcinomas.

Cancer investigation·2026
Same journal

The Association Between Lymphocyte-Monocyte Ratio, Tumor-Infiltrating Lymphocytes, and Tumor-Associated Macrophages with 3-Year Progression-Free Survival in Advanced Local Stage Nasopharyngeal Cancer Patients.

Cancer investigation·2026
Same journal

<i>In Vivo</i> Pharmacokinetics, Bio-Distribution and anti-Tumor Activity of Docetaxel-Loaded Folate Targeted Biocompatible Polymeric Micelles.

Cancer investigation·2026
Same journal

Bispecific Antibodies in Multiple Myeloma: A Concise Review of Current Treatments.

Cancer investigation·2026
Same journal

Adrenal Carcinoma Laterality is of Limited Clinical Significance: A National Perspective.

Cancer investigation·2026
See all related articles

Related Experiment Video

Updated: May 13, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Leukemic stem cells: a review.

J A O'Brien1, D A Rizzieri

  • 1Department of Medical Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA. Jenny.Obrien@duke.edu

Cancer Investigation
|March 12, 2013
PubMed
Summary
This summary is machine-generated.

Leukemic stem cells (LSCs) drive leukemia progression. Targeting these specific cells, identified as CD90(-), CD117(-), and CD123(+), offers a potential curative treatment for leukemia patients.

More Related Videos

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging
10:03

Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging

Published on: August 1, 2017

Related Experiment Videos

Last Updated: May 13, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging
10:03

Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging

Published on: August 1, 2017

Area of Science:

  • Hematology
  • Cancer Stem Cell Research
  • Immunophenotyping

Background:

  • Leukemia is driven by a small population of leukemic stem cells (LSCs).
  • LSCs originate from normal hematopoietic stem cells.
  • LSCs possess distinct surface markers: CD90(-), CD117(-), and CD123(+).

Purpose of the Study:

  • To identify and characterize leukemic stem cells (LSCs).
  • To explore therapeutic strategies targeting LSCs.
  • To evaluate the potential for LSC eradication in leukemia treatment.

Main Methods:

  • Utilizing mouse models to study LSC biology.
  • Employing immunophenotyping to distinguish LSCs from normal cells (CD90, CD117, CD123 markers).
  • Investigating potential therapeutic agents against LSCs.

Main Results:

  • Leukemic stem cells (LSCs) are confirmed as the drivers of leukemia proliferation.
  • Phenotypic markers (CD90(-), CD117(-), CD123(+)) reliably identify LSCs.
  • Mouse models suggest feasible therapeutic targets for LSCs.

Conclusions:

  • Targeting leukemic stem cells (LSCs) is a promising therapeutic strategy.
  • Elimination of LSCs may lead to efficient and potentially curative leukemia treatments.
  • Further research into LSC-specific therapies is warranted.